Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 39

1.

ONC201 activates ER stress to inhibit the growth of triple-negative breast cancer cells.

Yuan X, Kho D, Xu J, Gajan A, Wu K, Wu GS.

Oncotarget. 2017 Mar 28;8(13):21626-21638. doi: 10.18632/oncotarget.15451.

2.

Osteoprotegerin and breast cancer risk by hormone receptor subtype: a nested case-control study in the EPIC cohort.

Fortner RT, Sarink D, Schock H, Johnson T, Tjønneland A, Olsen A, Overvad K, Affret A, His M, Boutron-Ruault MC, Boeing H, Trichopoulou A, Naska A, Orfanos P, Palli D, Sieri S, Mattiello A, Tumino R, Ricceri F, Bueno-de-Mesquita HB, Peeters PH, Van Gils CH, Weiderpass E, Lund E, Quirós JR, Agudo A, Sánchez MJ, Chirlaque MD, Ardanaz E, Dorronsoro M, Key T, Khaw KT, Rinaldi S, Dossus L, Gunter M, Merritt MA, Riboli E, Kaaks R.

BMC Med. 2017 Feb 8;15(1):26. doi: 10.1186/s12916-017-0786-8.

3.

Calmodulin Binding to Death Receptor 5-mediated Death-Inducing Signaling Complex in Breast Cancer Cells.

Fancy RM, Kim H, Zhou T, Zinn KR, Buchsbaum DJ, Song Y.

J Cell Biochem. 2017 Aug;118(8):2285-2294. doi: 10.1002/jcb.25882. Epub 2017 Apr 12.

PMID:
28092099
4.

Double gene siRNA knockdown of mutant p53 and TNF induces apoptosis in triple-negative breast cancer cells.

Pileczki V, Pop L, Braicu C, Budisan L, Bolba Morar G, Del C Monroig-Bosque P, Sandulescu RV, Berindan-Neagoe I.

Onco Targets Ther. 2016 Nov 11;9:6921-6933. eCollection 2016.

5.

Synthesis, Crystal Study, and Anti-Proliferative Activity of Some 2-Benzimidazolylthioacetophenones towards Triple-Negative Breast Cancer MDA-MB-468 Cells as Apoptosis-Inducing Agents.

Abdel-Aziz HA, Eldehna WM, Ghabbour H, Al-Ansary GH, Assaf AM, Al-Dhfyan A.

Int J Mol Sci. 2016 Jul 29;17(8). pii: E1221. doi: 10.3390/ijms17081221.

6.
7.

Activated human mesenchymal stem/stromal cells suppress metastatic features of MDA-MB-231 cells by secreting IFN-β.

Yoon N, Park MS, Shigemoto T, Peltier G, Lee RH.

Cell Death Dis. 2016 Apr 14;7:e2191. doi: 10.1038/cddis.2016.90.

8.

Apoptosis/Necrosis Induction by Ultraviolet, in ER Positive and ER Negative Breast Cancer Cell Lines.

Shokrollahi Barough M, Hasanzadeh H, Barati M, Pak F, Kokhaei P, Rezaei-Tavirani M.

Iran J Cancer Prev. 2015 Dec;8(6):e4193. doi: 10.17795/ijcp-4193. Epub 2015 Dec 23.

9.

The TRAIL receptor agonist drozitumab targets basal B triple-negative breast cancer cells that express vimentin and Axl.

Dine JL, O'Sullivan CC, Voeller D, Greer YE, Chavez KJ, Conway CM, Sinclair S, Stone B, Amiri-Kordestani L, Merchant AS, Hewitt SM, Steinberg SM, Swain SM, Lipkowitz S.

Breast Cancer Res Treat. 2016 Jan;155(2):235-51. doi: 10.1007/s10549-015-3673-z. Epub 2016 Jan 12.

10.

Cytoplasmic levels of cFLIP determine a broad susceptibility of breast cancer stem/progenitor-like cells to TRAIL.

French R, Hayward O, Jones S, Yang W, Clarkson R.

Mol Cancer. 2015 Dec 15;14:209. doi: 10.1186/s12943-015-0478-y.

11.

Breast cancer genes PSMC3IP and EPSTI1 play a role in apoptosis regulation.

Capdevila-Busquets E, Badiola N, Arroyo R, Alcalde V, Soler-López M, Aloy P.

PLoS One. 2015 Jan 15;10(1):e0115352. doi: 10.1371/journal.pone.0115352. eCollection 2015.

12.

The role of Cullin3-mediated ubiquitination of the catalytic subunit of PP2A in TRAIL signaling.

Xu J, Zhou JY, Xu Z, Kho DH, Zhuang Z, Raz A, Wu GS.

Cell Cycle. 2014;13(23):3750-8. doi: 10.4161/15384101.2014.965068.

13.

TRAIL-mediated apoptosis in breast cancer cells cultured as 3D spheroids.

Chandrasekaran S, Marshall JR, Messing JA, Hsu JW, King MR.

PLoS One. 2014 Oct 24;9(10):e111487. doi: 10.1371/journal.pone.0111487. eCollection 2014.

14.

Diet and lifestyle factors modify immune/inflammation response genes to alter breast cancer risk and prognosis: the Breast Cancer Health Disparities Study.

Slattery ML, Lundgreen A, Torres-Mejia G, Wolff RK, Hines L, Baumgartner K, John EM.

Mutat Res. 2014 Dec;770:19-28.

15.

Combination therapy with anti-DR5 antibody and tamoxifen for triple negative breast cancer.

Kim H, Samuel SL, Zhai G, Rana S, Taylor M, Umphrey HR, Oelschlager DK, Buchsbaum DJ, Zinn KR.

Cancer Biol Ther. 2014 Aug;15(8):1053-60. doi: 10.4161/cbt.29183.

16.

Trail resistance induces epithelial-mesenchymal transition and enhances invasiveness by suppressing PTEN via miR-221 in breast cancer.

Wang H, Xu C, Kong X, Li X, Kong X, Wang Y, Ding X, Yang Q.

PLoS One. 2014 Jun 6;9(6):e99067. doi: 10.1371/journal.pone.0099067. eCollection 2014.

17.

Identification of novel molecular regulators of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis in breast cancer cells by RNAi screening.

Garimella SV, Gehlhaus K, Dine JL, Pitt JJ, Grandin M, Chakka S, Nau MM, Caplen NJ, Lipkowitz S.

Breast Cancer Res. 2014 Apr 17;16(2):R41. doi: 10.1186/bcr3645.

18.

Effect of niclosamide on basal-like breast cancers.

Londoño-Joshi AI, Arend RC, Aristizabal L, Lu W, Samant RS, Metge BJ, Hidalgo B, Grizzle WE, Conner M, Forero-Torres A, Lobuglio AF, Li Y, Buchsbaum DJ.

Mol Cancer Ther. 2014 Apr;13(4):800-11. doi: 10.1158/1535-7163.MCT-13-0555. Epub 2014 Feb 19.

19.

Plasminogen activator urokinase expression reveals TRAIL responsiveness and supports fractional survival of cancer cells.

Pavet V, Shlyakhtina Y, He T, Ceschin DG, Kohonen P, Perälä M, Kallioniemi O, Gronemeyer H.

Cell Death Dis. 2014 Jan 30;5:e1043. doi: 10.1038/cddis.2014.5.

20.

Early therapy assessment of combined anti-DR5 antibody and carboplatin in triple-negative breast cancer xenografts in mice using diffusion-weighted imaging and (1)H MR spectroscopy.

Zhai G, Kim H, Sarver D, Samuel S, Whitworth L, Umphrey H, Oelschlager DK, Beasley TM, Zinn KR.

J Magn Reson Imaging. 2014 Jun;39(6):1588-94. doi: 10.1002/jmri.24319. Epub 2013 Oct 22.

Supplemental Content

Support Center